在肺腺癌中开发与化相关的 lncRNA 风险模型和免疫治疗点分析
Xiang Xiong1, Wen Liu1, Chuan Yao1
1Department of Cardiothoracic Surgery, The Affiliated Hospital of Jiujiang University, Jiujiang, Jiangxi, China.
Frontiers in genetics
|April 23, 2025
概括
这项研究开发了一种预后模型,使用与结结相关的长非编码RNA (lncRNAs) 来预测肺腺癌 (LUAD) 的存活率和药物敏感性. 该模型确定了改善临床诊断和治疗策略的关键 lncRNA.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 肺癌是全球死亡率最高的疾病.
- 性化是一种依赖pH值的调节细胞死亡途径.
- 长非编码RNAs (lncRNAs) 在癌症发展中发挥作用.
研究的目的:
- 构建基于与化相关的肺腺癌 (LUAD) 的 lncRNAs 的预后模型.
- 为了确定潜在的治疗点,并预测LUAD患者的药物敏感性.
- 探索 lncRNAs,免疫透和瘤突变负担之间的关系.
主要方法:
- 利用TCGA数据库进行转录组,临床和突变数据.
- 采用多变量考克斯回归来识别预后性 lncRNA.
- 验证了预后模型并分析了免疫细胞透和瘤突变负担.
主要成果:
- 鉴定了155个与化相关的lncRNA,其中5个作为独立的预后因素.
- 开发的风险特征准确地预测了LUAD患者的无进展和整体存活率.
- 观察到染色体分离和免疫反应通路的显著丰富;药物敏感性在风险组之间有所不同.
结论:
- 一个与化相关的 lncRNA 预后模型提供了对 LUAD 诊断和治疗的见解.
- lncRNAs可以作为潜在的生物标志物,用于预测存活率和引导LUAD治疗.
- 药物敏感性分析有助于为高级的LUAD提供个性化治疗策略.
更多相关视频
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K